tiprankstipranks
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
US Market
RAPP
Rapport Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see RAPP full AI Analyst Report?

Rapport Therapeutics, Inc. (RAPP) Ratios

144 Followers

Rapport Therapeutics, Inc. Ratios

RAPP's free cash flow for Q1 2026 was $0.99. For the 2026 fiscal year, RAPP's free cash flow was decreased by $ and operating cash flow was $-1.21. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 27.08 26.17 35.34 17.14
Quick Ratio
 27.08 26.17 35.34 17.14
Cash Ratio
 4.36 2.76 6.48 7.97
Solvency Ratio
 -4.07 -3.98 -8.15 -0.19
Operating Cash Flow Ratio
 -4.49 -4.59 -7.39 -3.09
Short-Term Operating Cash Flow Coverage
 -30.71 -31.75 0.00 0.00
Net Current Asset Value
$ 458.61M$ 470.78M$ 300.30M$ -30.18M
Leverage Ratios
Debt-to-Assets Ratio
 0.02 0.02 <0.01 0.01
Debt-to-Equity Ratio
 0.02 0.02 <0.01 -0.08
Debt-to-Capital Ratio
 0.02 0.02 <0.01 -0.09
Long-Term Debt-to-Capital Ratio
 0.02 0.02 0.00 0.00
Financial Leverage Ratio
 1.06 1.06 1.03 -6.06
Debt Service Coverage Ratio
 -45.18 -45.04 0.00 0.00
Interest Coverage Ratio
 0.00 0.00 0.00 0.00
Debt to Market Cap
 <0.01 <0.01 0.00 0.00
Interest Debt Per Share
 0.23 0.24 0.07 0.01
Net Debt to EBITDA
 0.57 0.33 0.71 1.96
Profitability Margins
Gross Profit Margin
97.54%0.00%0.00%0.00%
EBIT Margin
-595.73%0.00%0.00%0.00%
EBITDA Margin
-590.73%0.00%0.00%0.00%
Operating Profit Margin
-611.03%0.00%0.00%0.00%
Pretax Profit Margin
-536.38%0.00%0.00%0.00%
Net Profit Margin
-536.38%0.00%0.00%0.00%
Continuous Operations Profit Margin
-536.38%0.00%0.00%0.00%
Net Income Per EBT
100.00%100.00%100.00%100.03%
EBT Per EBIT
87.78%89.12%94.28%96.12%
Return on Assets (ROA)
-21.56%-21.76%-24.86%-22.38%
Return on Equity (ROE)
-24.79%-23.00%-25.64%135.70%
Return on Capital Employed (ROCE)
-25.48%-25.36%-27.13%-24.68%
Return on Invested Capital (ROIC)
-25.34%-25.21%-27.06%-24.56%
Return on Tangible Assets
-21.56%-21.76%-24.86%-22.38%
Earnings Yield
-5.75%-7.82%-21.28%-0.93%
Efficiency Ratios
Receivables Turnover
 344.83 0.00 0.00 0.00
Payables Turnover
 0.07 0.24 0.43 0.04
Inventory Turnover
 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 1.69 0.00 0.00 0.00
Asset Turnover
 0.04 0.00 0.00 0.00
Working Capital Turnover Ratio
 0.04 0.00 0.00 0.00
Cash Conversion Cycle
 -4.87K -1.50K -850.07 -8.15K
Days of Sales Outstanding
 1.06 0.00 0.00 0.00
Days of Inventory Outstanding
 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 4.87K 1.50K 850.07 8.15K
Operating Cycle
 1.06 0.00 0.00 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
 -1.70 -1.86 -3.13 -0.15
Free Cash Flow Per Share
 -1.71 -1.88 -3.24 -0.16
CapEx Per Share
 <0.01 0.01 0.12 <0.01
Free Cash Flow to Operating Cash Flow
 1.00 1.01 1.04 1.06
Dividend Paid and CapEx Coverage Ratio
 -331.81 -142.00 -26.96 -16.61
Capital Expenditure Coverage Ratio
 -331.81 -142.00 -26.96 -16.61
Operating Cash Flow Coverage Ratio
 -7.43 -7.62 -43.92 -12.67
Operating Cash Flow to Sales Ratio
 -4.01 0.00 0.00 0.00
Free Cash Flow Yield
-5.59%-6.18%-18.27%-0.77%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -17.39 -12.79 -4.70 -108.10
Price-to-Sales (P/S) Ratio
 72.06 0.00 0.00 0.00
Price-to-Book (P/B) Ratio
 3.96 2.94 1.20 -146.70
Price-to-Free Cash Flow (P/FCF) Ratio
 -17.90 -16.18 -5.47 -130.49
Price-to-Operating Cash Flow Ratio
 -23.23 -16.29 -5.67 -138.35
Price-to-Earnings Growth (PEG) Ratio
 1.08 0.53 -0.02 -0.42
Price-to-Fair Value
 3.96 2.94 1.20 -146.70
Enterprise Value Multiple
 -11.63 -11.16 -4.03 -106.52
Enterprise Value
 1.37B 1.38B 312.57M 3.69B
EV to EBITDA
 -11.63 -11.16 -4.03 -106.52
EV to Sales
 68.70 0.00 0.00 0.00
EV to Free Cash Flow
 -17.06 -15.71 -4.65 -128.13
EV to Operating Cash Flow
 -17.11 -15.82 -4.82 -135.84
Tangible Book Value Per Share
 9.98 10.32 14.73 -0.14
Shareholders’ Equity Per Share
 9.98 10.32 14.73 -0.14
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 0.00 >-0.01
Revenue Per Share
 0.42 0.00 0.00 0.00
Net Income Per Share
 -2.27 -2.37 -3.78 -0.19
Tax Burden
 1.00 1.00 1.00 1.00
Interest Burden
 0.90 0.89 1.00 1.00
Research & Development to Revenue
 5.40 0.00 0.00 0.00
SG&A to Revenue
 1.71 0.00 0.00 0.00
Stock-Based Compensation to Revenue
 0.46 0.00 0.00 0.00
Income Quality
 0.92 0.78 0.83 0.78
Currency in USD